Key facts
- It has raised $37.5M; the latest was Later Stage VC in Sep 2025.
- Notable investors include European Union, Clave (Pamplona), Alzheimers Drug Discovery Foundation, BStartup10, Capital Cell — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for ADmit Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for ADmit Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ADmit Therapeutics
Developer of a medical diagnostic test designed for the early detection of Alzheimer's disease. The company's diagnostic test is based on an epigenetic analysis in blood samples that covers methylcytosines with next-generation sequencing, enabling medical practitioners to identify Alzheimer's and accelerate the identification of curative drugs in a simplified way.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2017
- Employees
- 10
- Website
- admit-therapeutics.com/
- Ownership
- Privately Held (backing)
ADmit Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ADmit Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ADmit Therapeutics in its N-PORT filings yet. We sweep new filings monthly.